Conduit Pharmaceuticals Company Insiders
| CDTTW Stock | 0.02 0.01 43.62% |
Conduit Pharmaceuticals employs about 7 people. The company is managed by 5 executives with a total tenure of roughly 17 years, averaging almost 3.0 years of service per executive, having 1.4 employees per reported executive. Recap of Conduit Pharmaceuticals' management performance can provide insight into the venture performance.
Conduit |
Conduit Pharmaceuticals Management Team Effectiveness
The company has return on total asset (ROA) of (3.2202) % which means that it has lost $3.2202 on every $100 spent on assets. This is way below average. Conduit Pharmaceuticals' management efficiency ratios could be used to measure how well Conduit Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.07 in 2024. Return On Capital Employed is likely to climb to -0.97 in 2024. At this time, Conduit Pharmaceuticals' Total Assets are fairly stable compared to the past year. Non Current Assets Total is likely to climb to about 1.6 M in 2024, whereas Intangible Assets are likely to drop 4,000 in 2024.Common Stock Shares Outstanding is likely to drop to about 37.6 M in 2024
Conduit Pharmaceuticals Workforce Comparison
Conduit Pharmaceuticals is number one stock in number of employees category among its peers. The total workforce of Health Care industry is currently estimated at about 110,431. Conduit Pharmaceuticals adds roughly 7.0 in number of employees claiming only tiny portion of equities under Health Care industry.
Conduit Pharmaceuticals Benchmark Summation
Operator |
The output start index for this execution was zero with a total number of output elements of sixty-one. Conduit Pharmaceuticals Price Series Summation is a cross summation of Conduit Pharmaceuticals price series and its benchmark/peer.
Conduit Pharmaceuticals Notable Stakeholders
A Conduit Pharmaceuticals stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Conduit Pharmaceuticals often face trade-offs trying to please all of them. Conduit Pharmaceuticals' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Conduit Pharmaceuticals' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| David Tapolczay | CEO Director | Profile | |
| James Bligh | Interim Director | Profile | |
| Adam Sragovicz | Chief Officer | Profile | |
| Joanne Holland | Chief Officer | Profile | |
| Bill Begien | Senior Relations | Profile |
About Conduit Pharmaceuticals Management Performance
The success or failure of an entity such as Conduit Pharmaceuticals often depends on how effective the management is. Conduit Pharmaceuticals management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Conduit management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Conduit management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.07) | (0.07) | |
| Return On Capital Employed | (1.03) | (0.97) | |
| Return On Assets | (0.07) | (0.08) | |
| Return On Equity | 1.17 | 0.61 |
Please note, the imprecision that can be found in Conduit Pharmaceuticals' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Conduit Pharmaceuticals. Check Conduit Pharmaceuticals' Beneish M Score to see the likelihood of Conduit Pharmaceuticals' management manipulating its earnings.
Conduit Pharmaceuticals Workforce Analysis
Traditionally, organizations such as Conduit Pharmaceuticals use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Conduit Pharmaceuticals within its industry.Conduit Pharmaceuticals Manpower Efficiency
Return on Conduit Pharmaceuticals Manpower
| Revenue Per Employee | 0.0 | |
| Revenue Per Executive | 0.0 | |
| Net Loss Per Employee | 76.4K | |
| Net Loss Per Executive | 107K | |
| Working Capital Per Employee | 561.7K | |
| Working Capital Per Executive | 786.4K |
Additional Tools for Conduit Stock Analysis
When running Conduit Pharmaceuticals' price analysis, check to measure Conduit Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Conduit Pharmaceuticals is operating at the current time. Most of Conduit Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Conduit Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Conduit Pharmaceuticals' price. Additionally, you may evaluate how the addition of Conduit Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.